Welcome to Advanced Search

Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Advancing Cancer Therapy: Harnessing In Vivo Tumor Models for Breakthrough Drug Development

Cancer therapy advancements In vivo tumor models Preclinical cancer research Drug development in oncology Gene-modified cell lines Immuno-oncology Tumor modeling for drug discovery Cancer drug development Animal modeling services Cancer drug preclinical models

Join us for an insightful webinar exploring the critical role of in vivo tumor models in advancing cancer drug therapy. We will provide an overview of the diverse tumor models developed by our company, highlighting case studies demonstrating their effectiveness in preclinical cancer research. The session will delve into the comprehensive use of gene-modified cell lines and genetically modified spontaneous mouse models, showcasing their application in mimicking human cancer biology. We will conclude with a brief introduction to our company and our commitment to accelerating cancer drug development through innovative animal modeling services.

Join Our Webinar: Applications of Humanized Mouse Models in Preclinical Research

Humanized mouse models preclinical research targeted therapies webinar oncology drug development preclinical therapeutic advancements immune system models animal modeling services

Join GenoBioTX's webinar on July 25th to explore the latest advancements in humanized mouse models for preclinical research. Learn how these models are transforming targeted therapy development across various diseases. Featuring expert insights from Dr. Derek Reznik, discover the generation and application of humanized immune system models in oncology drug development. Don't miss this opportunity to enhance your knowledge in cutting-edge preclinical therapeutic advancements. Register now!

Webinar on Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical Models

Antibody-Drug Conjugates ADC Development Preclinical Models Targeted Cancer Therapies GenoBioTX ADC Webinar Biopharma Research Oncology Biochemistry Cancer Treatment Preclinical Evaluation Monoclonal Antibodies Small Molecule Drugs

Join us for a webinar on June 26th, 2024, exploring the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs). Learn from Dr. Hua Wei, VP of the Industrial Clients Department at GenoBioTX, about ADC components, mechanisms, historical evolution, and future directions.

SMOC Launched U-HuDTMbase®, Inclusive Resource Library of Innovative Therapeutic Target-Humanized Mouse Models, to Accelerate Novel Drug Discovery

U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.

News Update: GenoBioTX and Crown Bioscience Sign Global Cooperation Agreement

Liver Cancer PDX Model

PDX PDX models Patient-derived Xenografts

Patient-derived Xenografts (PDX) are advanced preclinical oncology models for drug development. It offers a far better alternative for preclinical drug evaluation as compared to the conventional cell line-derived xenograft model.

Humanized Mice

NMG mice with human-derived CD34+ hematopoietic stem cells can be used for reconstruction of multi-lineage human immune cells, and represent effective model animals for studies on immuno-oncology and infectious diseases.

Humanized Mice

NMG and NMG-B2m mice transplanted with human-derived PBMC are suitable for short-term in vivo tests requiring mature T cell function, including studies on HIV infection, immuno-oncology and GvHD.

Evaluating the Efficacy of Tumor-targeted Antibody in vivo

immunotherapy immune checkpoint immune checkpoint genes

As the most frequently used animal model, mice have been widely applied in the evaluation of drug efficacy. However, the human immune checkpoint genes only share ~60% identity with their murine counterparts. Thus antibodies that recognize human proteins do not necessarily interact with murine proteins, making it inappropriate to use wild type mice for evaluating the in vivo efficacy of human-specific antibody. The humanized immune checkpoint mouse models (Immune-Hu models), which were independently developed by Shanghai Model Organisms Center, are ideal models to evaluate the efficacy of anti-tumor antibody therapy.